CULLINAN THERAPEUTICS INC (CGEM) Stock Price, Forecast & Analysis
USA - NASDAQ:CGEM - US2300311063 - Common Stock
CGEM Key Statistics, Chart & Performance
The current stock price of CGEM is 7.44 USD. In the past month the price decreased by -4.98%. In the past year, price decreased by -46.32%.
CGEM Latest News, Press Relases and Analysis
CGEM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.14 | 386.36B | ||
| AMGN | AMGEN INC | 14.8 | 174.25B | ||
| GILD | GILEAD SCIENCES INC | 14.43 | 146.60B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.26 | 107.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 69.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 866.08 | 57.90B | ||
| INSM | INSMED INC | N/A | 40.57B | ||
| NTRA | NATERA INC | N/A | 28.36B | ||
| BIIB | BIOGEN INC | 9.33 | 22.91B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.89 | 14.88B |
Related stock screener links
About CGEM
Company Profile
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 111 full-time employees. The company went IPO on 2021-01-08. The company has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
Company Info
CULLINAN THERAPEUTICS INC
One Main Street, Suite 1350
Cambridge MASSACHUSETTS 02142 US
CEO: Owen Hughes
Employees: 111
Phone: 16174104650
CULLINAN THERAPEUTICS INC / CGEM FAQ
What does CGEM do?
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 111 full-time employees. The company went IPO on 2021-01-08. The company has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
Can you provide the latest stock price for CULLINAN THERAPEUTICS INC?
The current stock price of CGEM is 7.44 USD. The price increased by 3.48% in the last trading session.
What is the dividend status of CULLINAN THERAPEUTICS INC?
CGEM does not pay a dividend.
What is the ChartMill technical and fundamental rating of CGEM stock?
CGEM has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for CULLINAN THERAPEUTICS INC?
CULLINAN THERAPEUTICS INC (CGEM) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of CULLINAN THERAPEUTICS INC (CGEM)?
CULLINAN THERAPEUTICS INC (CGEM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.31).
CGEM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CGEM. When comparing the yearly performance of all stocks, CGEM is a bad performer in the overall market: 88.79% of all stocks are doing better.
CGEM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CGEM. No worries on liquidiy or solvency for CGEM as it has an excellent financial health rating, but there are worries on the profitability.
CGEM Financial Highlights
Over the last trailing twelve months CGEM reported a non-GAAP Earnings per Share(EPS) of -3.31. The EPS decreased by -16.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.78% | ||
| ROE | -48.03% | ||
| Debt/Equity | 0 |
CGEM Forecast & Estimates
17 analysts have analysed CGEM and the average price target is 26.86 USD. This implies a price increase of 261.02% is expected in the next year compared to the current price of 7.44.